secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001193805-24-001257
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic: IDMC confirms Phase 3 ENSURE trials not futile, recommends continue as planned; CALLIPER data April 2025
--------------------------------------------------------------------------------

- IDMC recommended ENSURE-1 and ENSURE-2 continue unchanged; predetermined futility criteria not met.
- Sample size deemed appropriate to address primary endpoint of time to first relapse; no upsizing needed.
- Top-line data from Phase 2 CALLIPER trial in progressive MS expected April 2025.
- ENSURE program completion on track: ENSURE-1 in Q2 2026, ENSURE-2 in H2 2026.
- Immunic remains blinded; drug vidofludimus calcium is a Nurr1 activator for relapsing MS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524001257/0001193805-24-001257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524001257/e663960_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-001257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer